<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d539" origId="Cevimeline"><sentence id="DrugDDI.d539.s0" origId="s0" text="Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances."><entity id="DrugDDI.d539.s0.e0" origId="s0.p0" charOffset="0-10" type="drug" text="Cevimeline"/><entity id="DrugDDI.d539.s0.e1" origId="s0.p7" charOffset="66-93" type="drug" text="beta adrenergic antagonists"/><pair id="DrugDDI.d539.s0.p0" e1="DrugDDI.d539.s0.e0" e2="DrugDDI.d539.s0.e1" interaction="true"/></sentence><sentence id="DrugDDI.d539.s1" origId="s1" text="Drugs with parasympathomimetic effects administered concurrently with cevimeline can be expected to have additive effects."><entity id="DrugDDI.d539.s1.e0" origId="s1.p10" charOffset="0-5" type="drug" text="Drugs"/><entity id="DrugDDI.d539.s1.e1" origId="s1.p11" charOffset="11-30" type="drug" text="parasympathomimetic"/><entity id="DrugDDI.d539.s1.e2" origId="s1.p14" charOffset="70-80" type="drug" text="cevimeline"/><pair id="DrugDDI.d539.s1.p0" e1="DrugDDI.d539.s1.e0" e2="DrugDDI.d539.s1.e1" interaction="false"/><pair id="DrugDDI.d539.s1.p1" e1="DrugDDI.d539.s1.e0" e2="DrugDDI.d539.s1.e2" interaction="true"/><pair id="DrugDDI.d539.s1.p2" e1="DrugDDI.d539.s1.e1" e2="DrugDDI.d539.s1.e2" interaction="false"/></sentence><sentence id="DrugDDI.d539.s2" origId="s2" text="Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly."><entity id="DrugDDI.d539.s2.e0" origId="s2.p21" charOffset="0-10" type="drug" text="Cevimeline"/><entity id="DrugDDI.d539.s2.e1" origId="s2.p24" charOffset="42-56" type="drug" text="antimuscarinic"/><entity id="DrugDDI.d539.s2.e2" origId="s2.p25" charOffset="68-73" type="drug" text="drugs"/><pair id="DrugDDI.d539.s2.p0" e1="DrugDDI.d539.s2.e0" e2="DrugDDI.d539.s2.e1" interaction="true"/><pair id="DrugDDI.d539.s2.p1" e1="DrugDDI.d539.s2.e0" e2="DrugDDI.d539.s2.e2" interaction="true"/><pair id="DrugDDI.d539.s2.p2" e1="DrugDDI.d539.s2.e1" e2="DrugDDI.d539.s2.e2" interaction="false"/></sentence><sentence id="DrugDDI.d539.s3" origId="s3" text="Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline."><entity id="DrugDDI.d539.s3.e0" origId="s3.p28" charOffset="0-5" type="drug" text="Drugs"/><entity id="DrugDDI.d539.s3.e1" origId="s3.p31" charOffset="20-26" type="drug" text="CYP2D6"/><entity id="DrugDDI.d539.s3.e2" origId="s3.p38" charOffset="71-81" type="drug" text="cevimeline"/><pair id="DrugDDI.d539.s3.p0" e1="DrugDDI.d539.s3.e0" e2="DrugDDI.d539.s3.e1" interaction="false"/><pair id="DrugDDI.d539.s3.p1" e1="DrugDDI.d539.s3.e0" e2="DrugDDI.d539.s3.e2" interaction="true"/><pair id="DrugDDI.d539.s3.p2" e1="DrugDDI.d539.s3.e1" e2="DrugDDI.d539.s3.e2" interaction="false"/></sentence><sentence id="DrugDDI.d539.s4" origId="s4" text="Cevimeline should be used with caution in individuals known or suspected to be deficient in CYP2D6 activity, based on previous experience, as they may be at a higher risk of adverse events."><entity id="DrugDDI.d539.s4.e0" origId="s4.p39" charOffset="0-10" type="drug" text="Cevimeline"/><entity id="DrugDDI.d539.s4.e1" origId="s4.p51" charOffset="92-98" type="drug" text="CYP2D6"/><pair id="DrugDDI.d539.s4.p0" e1="DrugDDI.d539.s4.e0" e2="DrugDDI.d539.s4.e1" interaction="true"/></sentence><sentence id="DrugDDI.d539.s5" origId="s5" text="In an in vitro study, cytochrome P450 isozymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 were not inhibited by exposure to cevimeline."><entity id="DrugDDI.d539.s5.e0" origId="s5.p61" charOffset="22-51" type="drug" text="cytochrome P450 isozymes 1A2"/><entity id="DrugDDI.d539.s5.e1" origId="s5.p73" charOffset="120-130" type="drug" text="cevimeline"/><pair id="DrugDDI.d539.s5.p0" e1="DrugDDI.d539.s5.e0" e2="DrugDDI.d539.s5.e1" interaction="false"/></sentence></document>